CALR突变原发性血小板增多症患者的降细胞治疗:西班牙原发性血小板增多症登记研究比较不同基因型的指征与疗效
西班牙原发性血小板增多症登记研究纳入1446例患者(CALR突变267例,17%),评估降细胞治疗启动指征及常规疗效。低危患者中CALR阳性者自诊断至降细胞治疗时间短于其他基因型(CALR 2.8年、MPL 3.2年、JAK2V617F 7.4年、TN 12.5年,P<0.0001)。CALR突变者12个月完全血液学缓解(CR)累积率40%、JAK2V617F为67%,中位至CR时间CALR 705天、JAK2V617F 192天,CR持续时间较短(P=0.003),对羟基脲耐药/不耐受更频繁(CALR 23%、JAK2V617F 5%、MPL 27%、TN 15%,P<0.0001)。
要点
- 低危ET中CALR突变者降细胞治疗启动最早,中位2.8年。
- CALR突变者12个月CR累积率40%,低于JAK2V617F的67%。
- CALR突变者对羟基脲耐药/不耐受更频繁(23%),常规降细胞药物疗效较差。
核心结论
- 常规降细胞药物对CALR突变ET疗效较差,提示需要新治疗方式并重新定义该基因型患者的血液学治疗目标。
研究设计与样本
- 西班牙原发性血小板增多症登记研究,纳入1446例ET患者,其中CALR突变267例(17%),评估降细胞治疗启动指征及常规治疗反应。
主要发现
- 低危患者自诊断至降细胞治疗时间:CALR 2.8年、MPL 3.2年、JAK2V617F 7.4年、TN 12.5年(P<0.0001)。
- 1104例(76%)接受降细胞治疗:羟基脲977例、阿那格雷113例、其他14例。
- 12个月CR累积率:CALR 40% vs JAK2V617F 67%。
- 中位至CR时间:JAK2V617F 192天、TN 343天、MPL 433天、CALR 705天(P<0.0001)。
- CALR突变者CR持续时间短于其余患者(P=0.003);羟基脲耐药/不耐受:JAK2V617F 5%、CALR 23%、MPL 27%、TN 15%(P<0.0001)。
关键数值与推荐
- CALR阳性患者中羟基脲与阿那格雷在缓解率和缓解持续时间方面疗效相似。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The present study assessed the criteria for initiating cytoreduction and response to conventional therapies in 1446 patients with essential thrombocythemia (ET), 267 (17%) of which were CALR-mutated. In low risk patients, time from diagnosis to cytoreduction was shorter in CALR-positive than in the other genotypes (2·8, 3·2, 7·4 and 12·5 years for CALR, MPL, JAK2V617F and TN, respectively, P < 0·0001). A total of 1104 (76%) patients received cytoreductive treatment with hydroxycarbamide (HC) (n = 977), anagrelide (n = 113), or others (n = 14). The estimated cumulative rates of complete haematological response (CR) at 12 months were 40 % and 67% in CALR and JAK2V617F genotypes, respectively. Median time to CR was 192 days for JAK2V617F, 343 for TN, 433 for MPL, and 705 for CALR genotypes (P < 0·0001). Duration of CR was shorter in CALR-mutated ET than in the remaining patients (P = 0·003). In CALR-positive patients, HC and anagrelide had similar efficacy in terms of response rates and duration. CALR-mutated patients developed resistance/intolerance to HC more frequently (5%, 23%, 27% and 15% for JAK2V617F, CALR, MPL and TN, respectively; P < 0·0001). In conclusion, conventional cytoreductive agents are less effective in CALR-mutated ET, highlighting the need for new treatment modalities and redefinition of haematologic targets for patients with this genotype.
引用
- Alvarez-Larrán A, Angona A, Andrade-Campos M, et al. Cytoreductive treatment in patients with CALR-mutated essential thrombocythaemia: a study comparing indications and efficacy among genotypes from the Spanish Registry of Essential Thrombocythaemia. Br J Haematol. 2020. PMID: 32745264. doi:10.1111/bjh.16988
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。